Vir Biotechnology, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
VIR Nasdaq 2836 www.vir.bio

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vir Biotechnology, Inc.

Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now - Jan 23rd, 2025 11:35 pm
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why - Jan 10th, 2025 7:32 pm
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates - Jan 9th, 2025 4:42 pm
Vir Biotechnology Reports Promising Trial Results for Cancer Therapies - Jan 9th, 2025 1:18 pm
Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment - Jan 8th, 2025 9:06 pm
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC - Jan 8th, 2025 12:45 pm
Vir Biotechnology price target lowered to $14 from $15 at BofA - Jan 8th, 2025 12:25 pm
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Dec 18th, 2024 2:30 pm
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta - Dec 12th, 2024 9:05 pm
Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride - Dec 3rd, 2024 9:07 pm
Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely? - Dec 1st, 2024 1:11 pm
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs - Nov 26th, 2024 2:30 pm
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference - Nov 25th, 2024 2:30 pm
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - Nov 19th, 2024 2:15 am
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - Nov 18th, 2024 9:05 pm
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Nov 15th, 2024 6:39 pm
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - Nov 15th, 2024 4:00 pm
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Nov 4th, 2024 10:46 am
Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations - Nov 2nd, 2024 2:58 pm
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... - Nov 1st, 2024 9:01 pm